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Several epidemiologic studies have reported a protective
effect of oral contraceptives (OCs) on ovarian cancer. How-
ever, there remain open issues, including better quantifica-
tion of time-related factors such as time since last use, age at
first use and time since first use. We performed a collabora-
tive reanalysis of 6 case-control studies conducted between
1978 and 1999 in the United Kingdom, Greece and Italy,
including a total of 2,768 incident, histologically confirmed
cases of epithelial ovarian cancer and 6,274 hospital controls
under age 70 years. A reduced risk of ovarian cancer was
found for ever- compared to never-users [odds ratio (OR) 
0.66, 95% confidence interval (CI) 0.56–0.79], and a stronger
reduction was observed for women who had used OCs for>5
years (OR  0.50, 95% CI 0.33–0.76) compared to those who
had used them for <5 years. The protective effect of OCs on
ovarian cancer was consistent across strata of age, parity,
menopausal status and family history of breast or ovarian
cancer. After allowance for duration of use, no other time
factor was related to ovarian cancer risk: the reduced risk
was similar for women who stopped OC use >20 years be-
fore compared to <10 years; likewise, no significant modifi-
cation of risk reduction was observed for age at first OC use
and time since first OC use. The present analysis indicates
that, after taking into account duration of OC use, the OC
protection from ovarian cancer persists for a long time after
stopping use.
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Epidemiologic studies conducted since the late 1970s have
reported a protective effect of oral contraceptives (OCs) from
ovarian cancer and a stronger reduction of risk for longer duration
of use.1–3 An indication of a favorable impact of OC on ovarian
carcinogenesis comes also from descriptive epidemiology. In sev-
eral developed countries, young women have shown substantial
decreases in incidence of and mortality from ovarian cancer, and
the downward trends are greater in countries where OCs are
widely used.4–7
However, there remain open issues on the relation between OC
use and ovarian cancer, including a better quantification of time-
related factors, notably time since last use, age at first use and time
since first use. Some of the studies that have considered time since
last OC use have reported that the favorable effect of OCs on
ovarian cancer risk persists for at least 15 years after stopping
use.2,8–11 A few studies, however, have assessed the risk with
longer time since last use.12–16 A cohort analysis of ovarian cancer
incidence and mortality rates in U.S. women over the period
1970–19957 indicated that the relative decrease in incidence is
greater before age 50. There is, therefore, a suggestion that the
protection declines with time since last use, but the data are
inconclusive.2 In addition, few studies have simultaneously ad-
dressed all time factors, so the possibility of residual confounding
in some of these studies cannot be excluded.
To clarify the time relation between OC use and ovarian cancer
risk, we conducted a collaborative reanalysis of European case-
control studies of epithelial ovarian cancer.
MATERIAL AND METHODS
In the present analysis, data from 6 case-control studies con-
ducted in the United Kingdom, Greece and Italy were combined,
i.e., all studies on OC and ovarian cancer published from Europe.
The study design and methods have already been described.12
Briefly, the first was a hospital-based investigation conducted in
London and Oxford, UK, between 1978 and 1983.17 Cases were
235 women under 65 years of age with epithelial ovarian cancer;
controls were 451 women of comparable age, hospitalized for
gastrointestinal diseases (23%), bone or joint diseases including
fractures (22%) and a large number of other diagnostic categories,
each including 10% of the total number of controls.
The second study included 150 patients with malignant epithe-
lial tumors of the ovary, admitted during 1980 and 1981 to 10 large
hospitals of the Greater Athens area, Greece,18 and 250 controls of
similar age, hospitalized in the same time period in Athens hos-
pitals for orthopedic conditions (among which 62% were traumas).
The third study included 189 cases of epithelial ovarian cancer
admitted to 2 major hospitals in Athens between 1989 and 1991.19
Controls were 200 women, resident in the Greater Athens area,
visitors of patients hospitalized in the same ward as cases in the
same time period. Both cases and controls were below 75 years of
age.
The fourth study was a hospital-based investigation conducted
in the Greater Milan area, northern Italy, comprising a total of 971
patients under 75 years of age with epithelial cancer of the ovary,
admitted between 1983 and 1991 to the National Cancer Institute
and the Ospedale Maggiore.20 The control group included 2,578
women admitted to the same network of hospitals for acute con-
ditions (34% traumas, 30% nontraumatic orthopedic disorders,
16% surgical conditions and 20% other miscellaneous diseases).
Controls were comparable to cases in terms of age and area of
residence.
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The fifth study was conducted between 1992 and 1999 in 4
Italian areas, including Greater Milan, the provinces of Pordenone,
Padua and Gorizia (northern Italy), the province of Latina (central
Italy), and the urban area of Naples (southern Italy).21 Cases were
1,031 women under 79 years of age with incident ovarian cancer
admitted to major teaching and general hospitals in the areas under
study. Controls were 2,411 women resident in the same geographic
areas and admitted to the same network of hospitals as cases for
acute, non-neoplastic conditions unrelated to known or potential
risk factors for ovarian cancer (26% traumas, 28% nontraumatic
orthopedic disorders, 15% surgical conditions and 31% miscella-
neous other illnesses).
The last study was another Italian investigation, including 440
women with a diagnosis of epithelial ovarian cancer admitted
between 1988 and 1998 to the Department of Gynecologic Oncol-
ogy of the Catholic University Hospital in Rome.22 Controls were
868 women admitted to the same hospital for acute, nongyneco-
logic, nonhormonal and non-neoplastic conditions (29% traumatic
conditions, 21% nontraumatic orthopedic disorders, 17% acute
abdominal diseases and 33% other miscellaneous disorders).
Only women under 70 years of age were considered in the
present analysis, which thus includes a total 2,768 histologically
confirmed epithelial ovarian cancer cases and 6,274 corresponding
controls.
Data analysis
From the 6 original data sets, a single file was obtained, includ-
ing comparable variables coded in a uniform format. These in-
cluded age, an indicator of sociocultural level (based on social
class17–19 or education20–22), age at interview, parity, menopausal
status, age at menopause and various indicators of OC use. Infor-
mation on OC use (ever/never) was provided by all studies,
whereas information on duration of OC use was provided by all
except the first Greek study18 and age at first OC use was given
only in the UK17 and the 3 Italian studies.20–22 Data on family
history of breast or ovarian cancer in first-degree relatives were
available only in the 3 Italian studies.
Odds ratios (ORs) for various indicators of OC use and the
corresponding 95% confidence intervals (CIs) were estimated us-
ing an unconditional logistic regression model,23 including terms
for study center, age, year of interview, sociocultural level, parity,
menopausal status and age at menopause.
RESULTS
Table I gives the distribution of 2,768 ovarian cancer cases and
6,274 controls according to age and other selected variables. The
age distribution was similar for cases and controls. Cases had a
higher socioeducational level, were more frequently nulliparous,
reported a later age at menopause and a more frequent history of
breast or ovarian cancer in first-degree relatives.
The relation between various indicators of OC use and ovarian
cancer risk is presented in Table II. Overall, 9.2% of ovarian
cancer cases and 13.2% of controls were ever-users of OCs,
corresponding to an OR of 0.66 (95% CI 0.56–0.79), compared to
never-users.
The protective effect of OCs against ovarian cancer was con-
sistent across study centers, though the proportion of ever-users
ranged between 21.7% in the U.K. study and 4.6% in the 2 Greek
studies combined. Furthermore, no meaningful or consistent dif-
ferences in the apparent favorable effect were observed when
strata of age, parity, menopausal status and family history of breast
or ovarian cancer were considered (Fig. 1).
A stronger reduction of ovarian cancer risk was found for
women who had used OCs for a longer period (OR  0.83, 95%
CI 0.69–1.01 for duration of use 5 years; OR  0.42, 95% CI
0.30–0.59 for duration of use 5 years, with a significant trend of
decreasing risk). The beneficial effect on ovarian cancer was
observed for at least 20 years since last OC use (OR  0.77, 95%
CI 0.51–1.16 15–19 years after stopping OC use). Ovarian cancer
risk was lower for women reporting first use before 25 years of age
(OR  0.59, 95% CI 0.42–0.83) and after 15 years from first OC
use (OR 0.66, 95% CI 0.51–0.86), though these estimates could
partly confounded by duration of use.
When analyses were restricted to ever-users and allowance was
made for duration of OC use (Table III), no other time factor was
related to ovarian cancer risk: the reduced risk was similar for
women who stopped OC use 20 years before compared to 10
years (OR  0.81, 95% CI 0.40–1.66). Likewise, no significant
pattern of risk was observed for age at first OC use (OR  1.04,
95% CI 0.56–1.92 for age at first use 35 years compared to 25
years) and time since first OC use (OR  0.67, 95% CI 0.41–1.09
for 15 years since first use compared to 10 years).
DISCUSSION
The present analysis, conducted on the largest data set to date of
ovarian cancer, confirms the beneficial effect of OCs on ovarian
cancer and the stronger protection provided by a long duration of
use.2,3 Inadequate information was, however, available on the
possible role of other time-related factors, in particular the persis-
tence of any reduced risk long after stopping OC use. Our study
thus allows meaningful analyses of these time-related factors, with
specific reference to the absence of any attenuation of protection
with time since last OC use.
The protective effect of OCs was consistent in all studies in-
cluded in the analysis, notwithstanding the differences in the
prevalence of OC use, lifestyle and reproductive characteristics of
women from the various countries. Moreover, the inverse relation
between OC use and ovarian cancer was not confounded by age,
education and other risk factors for ovarian cancer, including
nulliparity, menopausal status and age at menopause. In particular,
when we analyzed the effect of OC use separately among nullip-
arous and parous women, no significant difference in the magni-
tude of protection was observed. This indicates that OCs are
unlikely to be simply an indirect marker of parity and fertility,11,24
which are inversely related to the risk of ovarian cancer.1,13 Fur-
thermore, an inverse relation between OC use and ovarian cancer
risk was present in women with and without a family history of
breast or ovarian cancer.25,26
TABLE I – DISTRIBUTION OF 2,768 OVARIAN CANCER CASES AND 6,274
CONTROLS ACCORDING TO AGE AND SELECTED VARIABLES
Cases Controls
Number % Number %
Age (years)
40 318 11.5 933 14.9
40–49 637 23.0 1,495 23.8
50–59 1,015 36.7 1,983 31.6
60–69 798 28.8 1,863 29.7
Sociocultural level1
Low 1,378 50.0 3,210 51.4
Medium 795 28.9 1,909 30.6
High 581 21.1 1,121 18.0
Parity1
0 621 22.5 1,176 18.8
1 499 18.1 1,308 20.9
2 924 33.6 2,055 32.8
3 710 25.8 1,730 27.6
Menopausal status1
Pre/peri 1,048 38.0 2,552 40.7
Post 1,708 62.0 3,717 59.3
Age at menopause1 (year)
50 765 0.65 1,863 0.50
50 924 0.55 1,838 0.50
Family history2
No 1,990 89.1 5,104 94.2
Yes 243 10.9 312 5.8
1The sum does not add up to the total because of some missing
values.–2Family history of breast or ovarian cancer in first-degree
relatives. Based only on Parazzini et al.,20 Chiaffarino et al.,21 and
Greggi et al.22
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With regard to time-related factors, the present analysis shows
that OCs convey protection for a long time after stopping use (at
least 20 years). An apparent leveling off of this effect after 20
years since last use was no more evident after taking into account
duration of use. Long-term protection from OCs has been
reported,8–11 though only a few studies had the opportunity to
observe long time intervals between OC use cessation and ovarian
cancer occurrence.12,13,15,16 Also, no attempt has previously been
made to simultaneously control for duration of OC use and other
time-related factors.
In our investigation, women who started using OCs at younger
ages and reported a longer time since first use had an apparent
stronger protection, which, however, appeared to be mainly attrib-
utable to a longer duration of use. Among the few studies that
considered these time-related factors, 2 reported that age at first
use was unrelated to ovarian cancer risk.16,27
FIGURE 1 – ORs of ovarian can-
cer and 95% CIs for ever- com-
pared to never-users of OCs in
strata of study and selected covari-
ates. Estimates from unconditional
logistic regression models included
terms for age, study center, year of
interview, sociocultural level, par-
ity, menopausal status and age at
menopause.
TABLE II – DISTRIBUTION OF OVARIAN CANCER CASES AND CONTROLS ACCORDING TO SELECTED
INDICATORS OF OC USE AND CORRESPONDING OR AND 95% CI
Cases Controls OR1 (95% CI)
OC use3
Never 2,476 5,444 12
Ever 255 830 0.66 (0.56–0.79)
Duration of OC use3,4 (months)
Never 2,347 5,251 12
60 202 539 0.83 (0.69–1.01)
60 46 242 0.42 (0.30–0.59)
2 trend (p value) 24.56 (0.0001)
Time since last OC use3,5 (years)
Never 1,876 4,492 12
10 95 288 0.74 (0.57–0.98)
10–14 44 138 0.75 (0.52–1.08)
15–19 38 113 0.77 (0.51–1.16)
20 27 52 0.86 (0.50–1.47)
Age at first OC use3,5 (years)
Never 1,876 4,492 12
25 54 216 0.59 (0.42–0.83)
25–34 103 299 0.80 (0.61–1.03)
35 48 120 0.73 (0.51–1.07)
Time since first OC use3,5 (years)
Never 1,876 4,492 12
10 69 182 0.90 (0.65–1.25)
10–14 39 150 0.64 (0.44–0.94)
15 97 303 0.66 (0.51–0.86)
1Estimates from unconditional logistic regression models, including terms for age, study center, year of
interview, sociocultural level, parity, menopausal status and age at menopause.–2Reference category.–
3The sum does not add up to the total because of some missing values.–4Information not provided by
Tzonou et al.18–5Information not provided by Tzonou et al.,18 Polychronopoulous et al.19 and Greggi
et al.22
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Among the limitations of our analysis are the absence of infor-
mation on the potency of progestin and estrogen28 and the potential
weaknesses of the original case-control studies, including a pos-
sible biased recall of past OC use and the possibility of more
careful surveillance of ovarian diseases in OC users; these biases,
however, were considered minor by the authors of the original
studies. Moreover, the consistency of results across various study
designs and populations weighs against the existence of major
bias. The advantage of our study is the possibility of comparing
and analyzing different data sets using a uniform format, while the
large data set allows more precise estimates and simultaneous
allowance of various time-related factors.
In conclusion, our study further quantifies the degree of protec-
tion conveyed by OCs on ovarian carcinogenesis and documents
its inverse relation with longer duration of use. It also indicates
that, after taking into account duration of OC use, the protection
persists for a long time after stopping OC use, whereas other
time-related factors appear to be unrelated to ovarian cancer risk.
The persistence of long-term protection from OCs against ovarian
cancer has major implications for individual risk assessment and
for public health since the incidence of ovarian cancer rises with
age and the disease is over 10-fold more frequent at age 60 than at
age 30.29
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